| Kathryn L Mcmullan, MD | |
|
323 E Riverside Dr, Ste 234, Eagle, ID 83616-6864 | |
| (208) 938-4080 | |
| (208) 938-8922 |
| Full Name | Kathryn L Mcmullan |
|---|---|
| Gender | Female |
| Speciality | Allergy & Immunology - Allergy |
| Location | 323 E Riverside Dr, Eagle, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538108089 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | M8497 (Idaho) | Primary |
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191118000551 |
News Archive
Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.
Matsushita (Panasonic) has announced its environment-related subsidiary, Matsushita Ecology Systems Co., Ltd., has developed a revolutionary SARS air filter.
On May 20, Dr. Tanmay Lele, professor in the Department of Biomedical Engineering at Texas A&M University, received a $5 million Recruitment of Established Investigators grant from the Cancer Prevention and Research Institute of Texas to further knowledge about cancer and how it progresses.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Mercy Health Services has selected its ProVation MD software for gastroenterology procedure documentation and coding. The software will be deployed in the Institute for Digestive Health and Liver Disease at Mercy.
Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn L Mcmullan, MD 323 E Riverside Dr, Ste 234, Eagle, ID 83616-6864 Ph: (208) 938-4080 | Kathryn L Mcmullan, MD 323 E Riverside Dr, Ste 234, Eagle, ID 83616-6864 Ph: (208) 938-4080 |
News Archive
Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.
Matsushita (Panasonic) has announced its environment-related subsidiary, Matsushita Ecology Systems Co., Ltd., has developed a revolutionary SARS air filter.
On May 20, Dr. Tanmay Lele, professor in the Department of Biomedical Engineering at Texas A&M University, received a $5 million Recruitment of Established Investigators grant from the Cancer Prevention and Research Institute of Texas to further knowledge about cancer and how it progresses.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Mercy Health Services has selected its ProVation MD software for gastroenterology procedure documentation and coding. The software will be deployed in the Institute for Digestive Health and Liver Disease at Mercy.
Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).
› Verified 7 days ago